A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
Epstein–Barr virus (EBV) infection is proved to be associated with clinicopathology of lymphoma. However, little is known about the relationship between EBV‐DNA status after treatment and prognosis. In this study, real‐time polymerase chain reaction (PCR) was used for quantitative detection of EBV‐D...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575058/ https://www.ncbi.nlm.nih.gov/pubmed/36065965 http://dx.doi.org/10.1111/jcmm.17543 |
_version_ | 1784811240731705344 |
---|---|
author | Qiu, Lihua Si, Junqi Kang, Junnan Chen, Zehui Nuermaimaiti, Rexidan Qian, Zhengzi Li, Lanfang Zhou, Shiyong You, Mingjian James Zhang, Huilai Tian, Chen |
author_facet | Qiu, Lihua Si, Junqi Kang, Junnan Chen, Zehui Nuermaimaiti, Rexidan Qian, Zhengzi Li, Lanfang Zhou, Shiyong You, Mingjian James Zhang, Huilai Tian, Chen |
author_sort | Qiu, Lihua |
collection | PubMed |
description | Epstein–Barr virus (EBV) infection is proved to be associated with clinicopathology of lymphoma. However, little is known about the relationship between EBV‐DNA status after treatment and prognosis. In this study, real‐time polymerase chain reaction (PCR) was used for quantitative detection of EBV‐DNA load in peripheral blood of all 26,527 patients with lymphoma, and the clinical characteristics and prognosis of 202 patients were retrospectively analysed, including 100 patients with positive EBV‐DNA and 102 randomly selected patients with negative EBV‐DNA. We found that the average rate of EBV‐DNA positivity in lymphomas was 0.376%, and EBV‐DNA‐positive patients presented higher risk with elevated lactate dehydrogenase (LDH) and β2‐MG level, B symptoms, secondary hemophagocytic syndrome and lower objective response rate compared to EBV‐DNA‐negative patients. Multivariate analysis revealed EBV‐DNA‐positive patients had inferior progression‐free survival (PFS) and overall survival (OS) and EBV‐DNA level before treatment was related to PFS but not OS of T/NK cell lymphoma. In T/NK cell lymphoma, EBV‐DNA converting negative after treatment was correlated with better PFS but not OS, and second‐line therapy could induce more EBV‐DNA‐negative conversion compared to CHOP‐based therapy. In all, EBV‐DNA positivity before treatment can be a biomarker representing the tumour burden and an independent prognostic factor. EBV‐DNA‐negative conversion after treatment is a good prognostic factor for T/NK cell lymphomas. |
format | Online Article Text |
id | pubmed-9575058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95750582022-10-17 A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma Qiu, Lihua Si, Junqi Kang, Junnan Chen, Zehui Nuermaimaiti, Rexidan Qian, Zhengzi Li, Lanfang Zhou, Shiyong You, Mingjian James Zhang, Huilai Tian, Chen J Cell Mol Med Original Articles Epstein–Barr virus (EBV) infection is proved to be associated with clinicopathology of lymphoma. However, little is known about the relationship between EBV‐DNA status after treatment and prognosis. In this study, real‐time polymerase chain reaction (PCR) was used for quantitative detection of EBV‐DNA load in peripheral blood of all 26,527 patients with lymphoma, and the clinical characteristics and prognosis of 202 patients were retrospectively analysed, including 100 patients with positive EBV‐DNA and 102 randomly selected patients with negative EBV‐DNA. We found that the average rate of EBV‐DNA positivity in lymphomas was 0.376%, and EBV‐DNA‐positive patients presented higher risk with elevated lactate dehydrogenase (LDH) and β2‐MG level, B symptoms, secondary hemophagocytic syndrome and lower objective response rate compared to EBV‐DNA‐negative patients. Multivariate analysis revealed EBV‐DNA‐positive patients had inferior progression‐free survival (PFS) and overall survival (OS) and EBV‐DNA level before treatment was related to PFS but not OS of T/NK cell lymphoma. In T/NK cell lymphoma, EBV‐DNA converting negative after treatment was correlated with better PFS but not OS, and second‐line therapy could induce more EBV‐DNA‐negative conversion compared to CHOP‐based therapy. In all, EBV‐DNA positivity before treatment can be a biomarker representing the tumour burden and an independent prognostic factor. EBV‐DNA‐negative conversion after treatment is a good prognostic factor for T/NK cell lymphomas. John Wiley and Sons Inc. 2022-09-06 2022-10 /pmc/articles/PMC9575058/ /pubmed/36065965 http://dx.doi.org/10.1111/jcmm.17543 Text en © 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Qiu, Lihua Si, Junqi Kang, Junnan Chen, Zehui Nuermaimaiti, Rexidan Qian, Zhengzi Li, Lanfang Zhou, Shiyong You, Mingjian James Zhang, Huilai Tian, Chen A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma |
title | A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma |
title_full | A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma |
title_fullStr | A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma |
title_full_unstemmed | A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma |
title_short | A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma |
title_sort | retrospective analysis of ebv‐dna status with the prognosis of lymphoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575058/ https://www.ncbi.nlm.nih.gov/pubmed/36065965 http://dx.doi.org/10.1111/jcmm.17543 |
work_keys_str_mv | AT qiulihua aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT sijunqi aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT kangjunnan aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT chenzehui aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT nuermaimaitirexidan aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT qianzhengzi aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT lilanfang aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT zhoushiyong aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT youmingjianjames aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT zhanghuilai aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT tianchen aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT qiulihua retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT sijunqi retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT kangjunnan retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT chenzehui retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT nuermaimaitirexidan retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT qianzhengzi retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT lilanfang retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT zhoushiyong retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT youmingjianjames retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT zhanghuilai retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma AT tianchen retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma |